首页> 外文期刊>Microsurgery. >Chimerism induction in vascularized bone marrow transplants augmented with bone marrow cells.
【24h】

Chimerism induction in vascularized bone marrow transplants augmented with bone marrow cells.

机译:血管化骨髓移植中骨髓细胞增强的嵌合体诱导。

获取原文
获取原文并翻译 | 示例
       

摘要

Composite tissue allografts (CTAs) are currently accepted in the clinic; however, long-term immunosuppression is still needed for allograft survival. The presence of donor-specific chimerism may induce tolerance. Thirty-six vascularized bone marrow transplantation (VBMT) allotransplantation were performed across MHC barrier under short-term protocol of 7-day alphabeta-TCRmAb and Cyclosporin A therapy to determine the efficacy of VBMT alone and VBMT augmented with donor bone marrow transplantation (BMT) in chimerism induction. Flow cytometry analysis revealed that VBMT supported with donor BMT directly into the bone resulted in chimerism augmentation and maintenance compared to VBMT. In vivo and in vitro tolerance testing showed prolonged survival of donor skin graft up to 35 days and moderate reactivity in MLR assay that suggests only tolerance induction. Transplantation of vascularized bone without chronic immunosuppression provides a substantial source of bone marrow cells, leading to the developmentof stable donor-specific chimerism.
机译:临床上目前接受复合组织同种异体移植物(CTA);但是,同种异体移植的存活仍然需要长期的免疫抑制。供体特异性嵌合体的存在可以诱导耐受性。在7天的Alphabeta-TCRmAb和环孢菌素A治疗的短期方案下,通过MHC屏障进行了36例血管化骨髓移植(VBMT)同种移植,以确定单独使用VBMT和通过供体骨髓移植(BMT)增强的VBMT的疗效在嵌合体诱导中。流式细胞仪分析显示,与VBMT相比,VBMT在供体BMT的支持下直接进入骨骼,导致嵌合现象的增强和维持。体内和体外耐受性测试显示供体皮肤移植物的存活时间延长至35天,并且在MLR分析中显示中等程度的反应性,这表明仅诱导耐受性。没有慢性免疫抑制的血管化骨移植提供了骨髓细胞的重要来源,导致稳定的供体特异性嵌合体的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号